Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity

[1]  J. Jones,et al.  A reversible phospho-switch mediated by ULK1 regulates the activity of autophagy protease ATG4B , 2017, Nature Communications.

[2]  P. Bastiaens,et al.  A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. , 2017, Angewandte Chemie.

[3]  K. Shokat,et al.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design , 2016, Nature Reviews Drug Discovery.

[4]  R. Ghirlando,et al.  Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ , 2016, Proceedings of the National Academy of Sciences.

[5]  P. Bastiaens,et al.  Identification of pyrazolopyridazinones as PDEδ inhibitors , 2016, Nature Communications.

[6]  V. Tin,et al.  Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation , 2016, Antioxidants & redox signaling.

[7]  Ozlem Keskin,et al.  Ras Conformational Ensembles, Allostery, and Signaling. , 2016, Chemical reviews.

[8]  Liang Liu,et al.  Hernandezine, a novel AMPK activator induces autophagic cell death in drug-resistant cancers , 2016, Oncotarget.

[9]  R. Amaravadi,et al.  Emerging strategies to effectively target autophagy in cancer , 2016, Oncogene.

[10]  Gregory McAllister,et al.  Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy , 2015, Proceedings of the National Academy of Sciences.

[11]  D. Hardie,et al.  Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? , 2015, Clinical Cancer Research.

[12]  Hang Yuan,et al.  ROS/Autophagy/Nrf2 Pathway Mediated Low-Dose Radiation Induced Radio-Resistance in Human Lung Adenocarcinoma A549 Cell , 2015, International journal of biological sciences.

[13]  Rui Huang,et al.  Identifying an essential role of nuclear LC3 for autophagy , 2015, Autophagy.

[14]  Xinbing Sui,et al.  Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib , 2014, Scientific Reports.

[15]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[16]  A. Criollo,et al.  Tumor Suppression and Promotion by Autophagy , 2014, BioMed research international.

[17]  R. Bernards,et al.  RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.

[18]  Xiuping Chen,et al.  Psoralidin induces autophagy through ROS generation which inhibits the proliferation of human lung cancer A549 cells , 2014, PeerJ.

[19]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[20]  Philipp M. Cromm,et al.  Small-molecule modulation of Ras signaling. , 2014, Nature chemical biology.

[21]  A. Wittinghofer,et al.  Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. , 2014, Journal of medicinal chemistry.

[22]  A. Thorburn,et al.  Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. , 2014, Cancer discovery.

[23]  Malte Schmick,et al.  KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport , 2014, Cell.

[24]  Eric H. Baehrecke,et al.  Self-consumption: the interplay of autophagy and apoptosis , 2014, Nature Reviews Molecular Cell Biology.

[25]  E. White,et al.  Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRASG12D-driven lung tumors , 2013, Autophagy.

[26]  P. Bastiaens,et al.  Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.

[27]  Nicole M. Baker,et al.  Cancer: Drug for an 'undruggable' protein , 2013, Nature.

[28]  S. Pervaiz,et al.  ROS, autophagy, mitochondria and cancer: Ras, the hidden master? , 2013, Mitochondrion.

[29]  D. Proia,et al.  Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib , 2012, Molecular Cancer Therapeutics.

[30]  E. Lapi,et al.  Autophagic activity dictates the cellular response to oncogenic RAS , 2012, Proceedings of the National Academy of Sciences.

[31]  Karnail Singh,et al.  K-RAS GTPase- and B-RAF kinase–mediated T-cell tolerance defects in rheumatoid arthritis , 2012, Proceedings of the National Academy of Sciences.

[32]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[33]  M. Philips.  Ras hitchhikes on PDE6δ , 2012, Nature Cell Biology.

[34]  P. Bastiaens,et al.  Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. , 2011, Nature chemical biology.

[35]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[36]  Scott E. Kern,et al.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.

[37]  T. Morio,et al.  Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. , 2011, Blood.

[38]  A. Fernández-Medarde,et al.  Ras in cancer and developmental diseases. , 2011, Genes & cancer.

[39]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[40]  C. Kenific,et al.  Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation , 2011, Molecular biology of the cell.

[41]  S. Gibson.  A matter of balance between life and death: Targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy , 2010, Autophagy.

[42]  Patrizia Agostinis,et al.  ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy , 2010, Autophagy.

[43]  C. Der,et al.  Ras history , 2010, Small GTPases.

[44]  Michalis V. Karamouzis,et al.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.

[45]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[46]  B. Levine,et al.  Cell biology: Autophagy and cancer , 2007, Nature.

[47]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[48]  K. Little.  The saga continues. , 1996, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[49]  Ruth Nussinov,et al.  A New View of Ras Isoforms in Cancers. , 2016, Cancer research.

[50]  J. Downward,et al.  Inhibiting the RAS-PI3K pathway in cancer therapy. , 2013, The Enzymes.

[51]  F. Tamanoi,et al.  Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. , 2013, The Enzymes.

[52]  J. Obrecht.  [Cancer therapy]. , 1977, Deutsche medizinische Wochenschrift.